Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic ... as a 1-count or 10-count package of 1 mg per 0.2 mL single-dose vials.

Kevin McCulloch, Xeris’s President and COO, expressed enthusiasm for the FDA approval and the partnership, highlighting the potential of Gvoke VialDx™ to modernize glucagon administration for ...

Ozempic is a solution given as a subcutaneous injection. Dosages can vary from ... There’s one pen with this strength, and it delivers 1-mg doses. 8 mg/3 mL of liquid solution.

The drug is given as an injection under the skin once per week ... used for maintenance dosages 1 mg, given after 4 weeks of the 0.5-mg dose if blood sugar levels are still unmanaged once per ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Income Tax department has completed the regular assessment under Section 143(3) and passed assessment order pertaining to AY ...